Extended Data Table 4 Profile of potential risk factors (from other studies) for virological failure at baseline

From: Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial

  1. * Table shows number of participants (and proportion of those assessed) with each potential risk factor or combination of risk factors for virological failure within the 401 participants in whom all 3 risk factors were assessed. The three risk factors are those identified in multivariable analyses of pooled data from previous trials of long-acting therapy (Orkin et al, Clin Infect Dis 2023; 77 (10) 1423-1431).
  2. RPV RAM(s) denotes rilpivirine resistance associated mutation(s)
  3. † In the previously-published model, 90% of the participants categorised as having the higher risk A6 or A1 subtype had subtype A6 virus, and 10% had subtype A1 virus. In the population of the current trial, all participants under the category of subtype A6 or A1 virus had subtype A1; there was no subtype A6 virus identified.
  4. ‡ Rilpivirine resistance mutations are those listed in the 2022 edition of the IAS–USA drug resistance mutations list (L100I, K101EP, E138AGKQR, V179L, Y181CIV, Y188L, H221Y, F227C,
  5. M230IL). RPV drug-resistance mutations listed as APOBEC context DRMs in the Stanford database and that occurred on a sequence considered to be affected by APOBEC editing were disregarded (not counted as a risk factor; E138K in 2 participants, M230I in 24 participants overall).
  6. § Obesity is defined as body mass index (BMI) ≥ 30 kg/m2. BMI is the weight in kilograms divided by the square of the height in meters. Table adapted with permission from ref. 8, Elsevier.
Back to article page